EQS-Adhoc: Vitruvia Medical AG: Year End results as of December 31, 2023
|
EQS-Ad-hoc: Vitruvia Medical AG / Key word(s): Annual Results/Annual Report Vitruvia Medical AG: Year End results as of December 31, 2023 Anglikon, May 1st , 2024: Vitruvia Medical AG achieved a result after taxes of CHF -243,864.40 in the past year 2023 compared to CHF -1,095,349.38 in the previous year. On a consolidated basis, Vitruvia Medical AG generated revenue of EUR 1,7575,724.00 (previous year: EUR 1,525,529.00) and earnings before interest, taxes, depreciation and amortization (EBITA) of EUR 61,078.00, compared with EUR -912,086.00 in the previous year. Earnings after taxes and amortization of goodwill amounted to EUR -535,435 compared with EUR -1,484,556 in the previous year LT technologies has achieved its sales and profit expectations for 2023. For 2024, we expect LT technologies' activity to continue to pick up, which will be reflected in the sales and profit figures.
About Vitruvia Medical AG: Vitruvia Medical AG is a Swiss investment company focusing on the repair, production and trade of medical devices as well as surgical instruments. Vitruvia thus combines innovative and sustainable solutions for medical-technical progress, customer benefit and economic success.
End of Inside Information
01-May-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Vitruvia Medical AG |
| Kesselackerstr. 18 | |
| 5611 Anglikon | |
| Switzerland | |
| Phone: | +41 44 915 33 78 |
| E-mail: | kontakt@vitruvia-med.com |
| Internet: | www.vitruvia-med.com |
| ISIN: | CH0461931419 |
| WKN: | A2PDWF |
| Listed: | Regulated Unofficial Market in Munich |
| EQS News ID: | 1893569 |
| End of Announcement | EQS News Service |
|
|
1893569 01-May-2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 0,00 | 0,00 | 5,60 | 1,97 | 1,42 | 1,75 | 0,00 | |
| EBITDA1,2 | 0,00 | 0,00 | -0,96 | -0,75 | -0,91 | 0,06 | 0,00 | |
| EBITDA-Margin3 | 0,00 | 0,00 | -17,14 | -38,07 | -64,09 | 3,43 | 0,00 | |
| EBIT1,4 | 0,00 | 0,00 | -1,31 | -7,69 | -1,24 | -0,37 | 0,00 | |
| EBIT-Margin5 | 0,00 | 0,00 | -23,39 | -390,36 | -87,32 | -21,14 | 0,00 | |
| Net Profit (Loss)1 | 0,00 | 0,00 | -1,54 | -7,71 | -1,48 | -0,54 | 0,00 | |
| Net-Margin6 | 0,00 | 0,00 | -27,50 | -391,37 | -104,23 | -30,86 | 0,00 | |
| Cashflow1,7 | 0,00 | 0,00 | -0,21 | -0,78 | -0,67 | -0,10 | 0,00 | |
| Earnings per share8 | 0,00 | 0,00 | -0,85 | -4,19 | -0,59 | -0,21 | -0,09 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: BDO
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Vitruvia Medical | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A2PDWF | CH0461931419 | AG | 2,51 Mio € | 11.05.2021 | 8FVC9778+HW | |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| -25,00 | 0,00 | 0,00 | -0,40 | -5,02 | -24,15 | 1,44 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 24.06.2024 | 30.09.2024 | 01.05.2024 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +84,50% | +94,93% | -16,67% | -16,67% | -95,58% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
